Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2011, Article ID 132958, 14 pages
http://dx.doi.org/10.4061/2011/132958
Research Article

A Nonsecosteroidal Vitamin D Receptor Modulator Ameliorates Experimental Autoimmune Encephalomyelitis without Causing Hypercalcemia

1Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
2Research Opetation, NovaDigm Therapeutics, Inc., Grand Forks, ND 58202, USA
3Harvard Medical School, Harvard University, Boston, MA 02215, USA
4Respiratory and Immunology, External Discovery and Preclinical Sciences, Merck Research Laboratories, West Point, PA 19486, USA

Received 3 October 2010; Revised 10 December 2010; Accepted 19 December 2010

Academic Editor: Rachel Farrell

Copyright © 2011 Songqing Na et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Swanborg, “Animal models of human disease. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease,” Clinical Immunology and Immunopathology, vol. 77, no. 1, pp. 4–13, 1995. View at Google Scholar · View at Scopus
  2. G. G. Schwartz, “Multiple sclerosis and prostate cancer: what do their similar geographies suggest?” Neuroepidemiology, vol. 11, no. 4-6, pp. 244–254, 1992. View at Google Scholar · View at Scopus
  3. A. E. Handel, G. Giovannoni, G. C. Ebers, and S. V. Ramagopalan, “Environmental factors and their timing in adult-onset multiple sclerosis,” Nature Reviews Neurology, vol. 6, no. 3, pp. 156–166, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. K. L. Munger, S. M. Zhang, E. O'Reilly, M. A. Hernán, M. J. Olek, W. C. Willett, and A. Ascherio, “Vitamin D intake and incidence of multiple sclerosis,” Neurology, vol. 62, no. 1, pp. 60–65, 2004. View at Google Scholar · View at Scopus
  5. M. Soilu-Hänninen, L. Airas, I. Mononen, A. Heikkilä, M. Viljanen, and A. Hänninen, “25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis,” Multiple Sclerosis, vol. 11, no. 3, pp. 266–271, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. M. T. Cantorna, C. E. Hayes, and H. F. Deluca, “1,25-dihydroxyvitamin D reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 15, pp. 7861–7864, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. D. J. Mangelsdorf, C. Thummel, and C. Thummel, “The nuclear receptor super-family: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995. View at Google Scholar · View at Scopus
  8. S. Nagpal, S. Na, and R. Rathnachalam, “Noncalcemic actions of vitamin D receptor ligands,” Endocrine Reviews, vol. 26, no. 5, pp. 662–687, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. J. Bettoun, T. P. Burris, and T. P. Burris, “Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation,” Molecular Endocrinology, vol. 17, no. 11, pp. 2320–2328, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. B. D. Lemon and L. P. Freedman, “Selective effects of ligands on vitamin D receptor- and retinoid X receptor-mediated gene activation in vivo,” Molecular and Cellular Biology, vol. 16, no. 3, pp. 1006–1016, 1996. View at Google Scholar · View at Scopus
  11. C. Rachez and L. P. Freedman, “Mechanisms of gene regulation by vitamin D receptor: a network of coactivator interactions,” Gene, vol. 246, no. 1-2, pp. 9–21, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Niino, “Vitamin D and its immunoregulatory role in multiple sclerosis,” Drugs of Today, vol. 46, no. 4, pp. 279–290, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. Y. Ma, B. Khalifa, and B. Khalifa, “Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators,” Journal of Clinical Investigation, vol. 116, no. 4, pp. 892–904, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. Bouillon, W. H. Okamura, and A. W. Norman, “Structure-function relationships in the vitamin D endocrine system,” Endocrine Reviews, vol. 16, no. 2, pp. 200–256, 1995. View at Google Scholar · View at Scopus
  15. S. J. Van Cromphaut, M. Dewerchin, and M. Dewerchin, “Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 23, pp. 13324–13329, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. F. Bronner, “Mechanisms of intestinal calcium absorption,” Journal of Cellular Biochemistry, vol. 88, no. 2, pp. 387–393, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. L. Xiaodong and V. Huebner, “Non-steroidal ligands for steroid hormone receptors,” Current Opinion in Drug Discovery and Development, vol. 3, no. 4, pp. 383–398, 2000. View at Google Scholar · View at Scopus
  18. C. L. Smith and B. W. O'Malley, “Coregulator function: a key to understanding tissue specificity of selective receptor modulators,” Endocrine Reviews, vol. 25, no. 1, pp. 45–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Boguslawski, L. V. Hale, X. P. Yu, R. R. Miles, J. E. Onyia, R. F. Santerre, and S. Chandrasekhar, “Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways,” Journal of Biological Chemistry, vol. 275, no. 2, pp. 999–1006, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. R. J. Wood, L. Tchack, and S. Taparia, “1,25-Dihydroxyvitamin D3 increases the expression of the CaT1 epithelial calcium channel in the Caco-2 human intestinal cell line,” BMC Physiology, vol. 1, no. 1, article 11, p. 11, 2001. View at Google Scholar · View at Scopus
  21. A. R. Giuliano and R. J. Wood, “Vitamin D-regulated calcium transport in Caco-2 cells: unique in vitro model,” American Journal of Physiology, vol. 260, no. 2, pp. G207–G212, 1991. View at Google Scholar · View at Scopus
  22. D. J. Mekala, R. S. Alli, and T. L. Geiger, “IL-10-dependent suppression of experimental allergic encephalomyelitis by Th2-differentiated, anti-TCR redirected T lymphocytes,” Journal of Immunology, vol. 174, no. 6, pp. 3789–3797, 2005. View at Google Scholar
  23. D. A. Fernandes de Abreu, D. Eyles, and F. Féron, “Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases,” Psychoneuroendocrinology, vol. 34, no. 1, pp. S265–S277, 2009. View at Publisher · View at Google Scholar · View at PubMed
  24. C. Mathieu and L. Adorini, “The coming of age of 1,25-dihydroxyvitamin D analogs as immunomodulatory agents,” Trends in Molecular Medicine, vol. 8, no. 4, pp. 174–179, 2002. View at Publisher · View at Google Scholar
  25. M. T. Cantorna, C. E. Hayes, and H. F. DeLuca, “1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis,” Journal of Nutrition, vol. 128, no. 1, pp. 68–72, 1998. View at Google Scholar
  26. M. T. Cantorna, C. Munsick, C. Bemiss, and B. D. Mahon, “1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease,” Journal of Nutrition, vol. 130, no. 11, pp. 2648–2652, 2000. View at Google Scholar
  27. F. Mattner, S. Smiroldo, and S. Smiroldo, “Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D,” European Journal of Immunology, vol. 30, no. 2, pp. 498–508, 2000. View at Publisher · View at Google Scholar
  28. T. Koizumi, Y. Nakao, and T. Matsui, “Effects of corticosteroid and 1,24R-dihydroxy-vitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MP-lpr/lpr mice,” International Archives of Allergy and Applied Immunology, vol. 77, no. 4, pp. 396–404, 1985. View at Google Scholar
  29. C. Mathieu, M. Waer, J. Laureys, O. Rutgeerts, and R. Bouillon, “Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D,” Diabetologia, vol. 37, no. 6, pp. 552–558, 1994. View at Google Scholar
  30. C. Mathieu, M. Waer, K. Casteels, J. Laureys, and R. Bouillon, “Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D, KH1060,” Endocrinology, vol. 136, no. 3, pp. 866–872, 1995. View at Google Scholar
  31. J. Tang, R. U. Zhou, and R. U. Zhou, “Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response,” Journal of Immunology, vol. 182, no. 8, pp. 4624–4632, 2009. View at Publisher · View at Google Scholar · View at PubMed
  32. G. Laverny, G. Penna, S. Vetrano, C. Correale, M. Nebuloni, S. Danese, and L. Adorini, “Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease,” Immunology Letters, vol. 131, pp. 49–58, 2010. View at Publisher · View at Google Scholar · View at PubMed